Hepatology
Experts in the development and management of all aspects of MASH/MASLD, and viral hepatitis clinical trials
The voice of MASH investigators
Global survey provides insights for trial operations
Metabolic dysfunction-associated steatohepatitis (MASH), a component of metabolic syndrome, is an area of very active clinical development. To help determine the impact of this competitive environment for available and qualified site resources, as well as eligible patients, ICON undertook a global survey of MASH clinical trial sites across 37 different countries.
Digital solutions to alleviate MASH clinical trial challenges
The performance of MASH clinical trials presents many challenges unique to the field. Watch the on-demand webinar to learn about:
- The ability for digital technologies MRI, MRE and whole slide imaging to address MASH clinical trial challenges
- The ability of MRI and MRE to provide timely, high quality non-invasive solutions to enrolment
- The ability of whole slide imaging to facilitate rapid complex workflows that assure consistent high quality assessments of primary efficacy endpoints by enabling expert histopathologists to interact remotely and in real time.
Helping MASH study sites to succeed
Get insights and feedback from our extensive MASH study experience, and the findings from ICON’s survey of more than 2,000 sites across 30 countries including:
- How to best support global MASH sites to succeed in a competitive environment
- Optimising the operational strength of study sites to collectively support the MASH pipeline
- How understanding global and regional nuances can enhance MASH site patient recruitment and operational strategy
Metabolic dysfunction-associated steatohepatitis (MASH) clinical trials
Join Andrew Roche, PhD, a senior member of ICON's MASH team, as he speaks about overcoming the challenges and considerations associated with MASH Clinical Trials and examination of potential strategies to address during trial design or study execution.
-
Media article: Expanding diagnostic and biomarker options to improve MASH clinical trials
The absence of sufficient and accessible diagnostics for metabolic dysfunction-associated steatohepatitis (MASH) studies can complicate trials and impair clinical study conduct, as diagnostics are essential for disease detection, confirmation, and monitoring.
-
Blog: Obesity-related liver conditions: Understanding treatment options
Explore obesity’s role in liver disease progression and the value of different treatment options providing renewed hope to patients.
-
Media article: Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
.png?crop=yes&w=545&h=286&itok=6qbpsORW "ICON Hospital Shoot (14)")
Media article: Insight into obesity-related clinical research
In an interview with Contract Pharma, ICON’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
Media article: Diabesity: Implications for treatment and drug development
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
Media article: ICON survey stresses combo therapies in obesity care
This news piece from The Clinical Trial Vanguard provides an overview of the findings from ICON’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
-
Media article: A Special Report on Liver Disease: The Phantom Menace
ICON's Martin Benson provides expert commentary on liver disease in this December 2019 DDN News article.
-
Media article: NASH Clinical Trials – An Outlook on Challenges and Advances
Andrew Roche discusses the challenges of delayed diagnosis, and under diagnosis, of NASH, the impact on NASH clinical trials, and important NASH endpoints being considered.
.png?crop=yes&w=1382&h=727&a=0,98&itok=u55g9TrV "ICON Hospital Shoot (14)"){kind=icon}
Hepatology solutions
Discover more about ICON's solutions in the development and management of all aspects of MASH/MASLD, and viral hepatitis clinical trials clinical trials experts.